recent clinical trials are exploring promising new avenues for treating metastatic and locally advanced breast cancer. These studies investigate various therapeutic approaches, often combining established treatments with innovative compounds. Here’s a look at some key research currently underway:
A phase 3 study is evaluating the efficacy and safety of elacestrant, an oral selective estrogen receptor degrader (SERD), in comparison to standard endocrine therapy. This trial focuses on individuals with estrogen receptor-positive (ER+),HER2-negative advanced or metastatic breast cancer who have progressed on prior endocrine therapy.
Another significant trial examines the potential of datopotamab deruxtecan, an antibody-drug conjugate, in combination with pembrolizumab. This research targets individuals with advanced or metastatic HER2-low breast cancer who have previously received one or more lines of systemic therapy.
Furthermore, researchers are investigating the combination of samuraciclib and fulvestrant. This study specifically targets individuals with metastatic or locally advanced breast cancer.
Here’s a breakdown of these trials for your reference:
* Elacestrant vs. Standard Endocrine Therapy: This phase 3 trial assesses a novel SERD for ER+/HER2- advanced breast cancer.
* Datopotamab Deruxtecan + Pembrolizumab: This study explores a new combination for HER2-low advanced breast cancer.
* Samuraciclib + Fulvestrant (SUMIT-BC): This trial investigates a combination therapy for metastatic or locally advanced breast cancer.
I’ve found that staying informed about these clinical trials can empower you to discuss potential treatment options with your healthcare provider. Remember, participation in clinical trials is a personal decision, and it’s crucial to weigh the potential benefits and risks carefully.
Here’s what works best when considering trial participation:
- Discuss your medical history and treatment goals with your oncologist.
- Understand the trial’s purpose, procedures, and potential side effects.
- Ask questions about eligibility criteria and the commitment involved.
These ongoing studies represent a significant step forward in the fight against breast cancer. They offer hope for improved outcomes and a better quality of life for those affected by this disease.